GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Pear Therapeutics Inc (OTCPK:PEARQ) » Definitions » Earnings per Share (Diluted)

Pear Therapeutics (Pear Therapeutics) Earnings per Share (Diluted) : $-0.54 (TTM As of Dec. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Pear Therapeutics Earnings per Share (Diluted)?

Pear Therapeutics's Earnings per Share (Diluted) for the three months ended in Dec. 2022 was $-0.19. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2022 was $-0.54.

Pear Therapeutics's EPS (Basic) for the three months ended in Dec. 2022 was $-0.19. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2022 was $-0.54.

Pear Therapeutics's EPS without NRI for the three months ended in Dec. 2022 was $-0.22. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2022 was $-0.84.


Pear Therapeutics Earnings per Share (Diluted) Historical Data

The historical data trend for Pear Therapeutics's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pear Therapeutics Earnings per Share (Diluted) Chart

Pear Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Earnings per Share (Diluted)
-0.07 -0.78 -0.57 -0.54

Pear Therapeutics Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.13 -0.17 0.04 -0.22 -0.19

Competitive Comparison of Pear Therapeutics's Earnings per Share (Diluted)

For the Health Information Services subindustry, Pear Therapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pear Therapeutics's PE Ratio Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Pear Therapeutics's PE Ratio distribution charts can be found below:

* The bar in red indicates where Pear Therapeutics's PE Ratio falls into.



Pear Therapeutics Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Pear Therapeutics's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2022 is calculated as

Diluted Earnings Per Share (A: Dec. 2022 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-75.491-0)/138.707
=-0.54

Pear Therapeutics's Earnings Per Share (Diluted) for the quarter that ended in Dec. 2022 is calculated as

Diluted Earnings Per Share (Q: Dec. 2022 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-26.371-0)/139.720
=-0.19

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


Pear Therapeutics  (OTCPK:PEARQ) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Pear Therapeutics Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Pear Therapeutics's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Pear Therapeutics (Pear Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
200 State Street, 13th Floor, Boston, MA, USA, 02109
Pear Therapeutics Inc is a commercial-stage healthcare company pioneering a new class of software-based medicines, sometimes referred to as Prescription Digital Therapeutics (PDTs), which use software to treat diseases directly. The company's vision is to advance healthcare through the widespread use of PDTs and to be the one-stop shop for PDTs offered by Pear and other organizations that may choose to make their products available to patients, providers, and payors via its commercial platform, known as PearConnect. It features four distinct system components, consisting of PDTs for patient use, the PearMD Clinician Dashboard, an end-to-end patient service center, and a data analytics system configured to aggregate patient engagement, adherence, and clinical outcome data.
Executives
5am Partners Iv, Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Erin K. Brenner officer: Chief Product Dev. Officer C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Julia Strandberg officer: Chief Commercial Officer C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Ronan O'brien officer: General Counsel & Secretary C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Mccann Corey director, officer: President and CEO C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Yuri Maricich officer: Chief Medical Officer C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Ellen Snow officer: Chief Accounting Officer C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Christopherd T Guiffre officer: CFO, COO, Treas., & Asst. Sec. 65 HAYDEN AVE, LEXINGTON MA 02421
Katherine Jeffery officer: Chief People Officer C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Paul Mango director C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Timothy A Wicks director C/O PRECISION CASTPARTS CORP., 4650 SW MACADAM AVENUE, SUITE 400, PORTLAND OR 97239
Shivakumar Rajaraman director 6260 LOOKOUT ROAD, BOULDER CO 80301
Klp Spac 1 Llc 10 percent owner 195 CHURCH STREET , 15TH FLOOR, NEW HAVEN CT 06510
Zack Lynch director C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Elbrus Investments Pte. Ltd. 10 percent owner 60B ORCHARD ROAD #06-18, THE ATRIUM@ORCHARD, SINGAPORE U0 238891

Pear Therapeutics (Pear Therapeutics) Headlines

From GuruFocus

Pear Therapeutics to Participate in the Jefferies Healthcare Conference

By Business Wire Business Wire 06-02-2022

Pear Therapeutics Announces Process Exploring Strategic Alternatives

By Business Wire Business Wire 03-17-2023

Pear Therapeutics to Host Inaugural Virtual Investor Day on June 6, 2022

By Business Wire Business Wire 05-19-2022